Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Receivables - Net: 2019-2025

Historic Receivables - Net for Silence Therapeutics (SLN) over the last 4 years, with Sep 2025 value amounting to $28,000.

  • Silence Therapeutics' Receivables - Net fell 92.52% to $28,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $28,000, marking a year-over-year decrease of 92.52%. This contributed to the annual value of $972,000 for FY2024, which is 235.17% up from last year.
  • Per Silence Therapeutics' latest filing, its Receivables - Net stood at $28,000 for Q3 2025, which was down 67.06% from $85,000 recorded in Q2 2025.
  • Silence Therapeutics' 5-year Receivables - Net high stood at $15.4 million for Q2 2023, and its period low was $28,000 during Q3 2025.
  • For the 3-year period, Silence Therapeutics' Receivables - Net averaged around $2.9 million, with its median value being $585,208 (2023).
  • In the last 5 years, Silence Therapeutics' Receivables - Net surged by 496.74% in 2022 and then slumped by 99.60% in 2025.
  • Over the past 5 years, Silence Therapeutics' Receivables - Net (Quarterly) stood at $446,191 in 2021, then spiked by 140.53% to $1.1 million in 2022, then slumped by 72.98% to $290,000 in 2023, then surged by 235.17% to $972,000 in 2024, then plummeted by 92.52% to $28,000 in 2025.
  • Its Receivables - Net stands at $28,000 for Q3 2025, versus $85,000 for Q2 2025 and $41,000 for Q1 2025.